QPPV.COM KNOWLEDGE ASSESSMENT

Catumaxomab: Classification, Mechanism, Authorisation History and Pharmacovigilance

Test your understanding of the concepts covered by Catumaxomab: Classification, Mechanism, Authorisation History and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient develops abdominal pain and fever after an infusion and a recent ascites-drainage procedure. Which case-processing approach is most appropriate?

Retain the reported symptoms and clinician's assessment, and evaluate treatment timing alongside the procedure and other plausible causes. Attribute the symptoms to catumaxomab because they followed an infusion. Attribute the symptoms to the drainage procedure and exclude the medicine from assessment. Replace the symptoms with a diagnosis of peritoneal infection even if no clinician made that diagnosis.

Question 2 of 10 Why should catumaxomab's safety profile not be interpreted as though it were a conventional monospecific antibody?

Its ability to bring several immune-cell populations into proximity makes inflammatory effects biologically plausible and clinically relevant. Its intraperitoneal route means systemic adverse reactions cannot occur. Its Fc region prevents immune activation, so inflammatory symptoms should be presumed unrelated. Its tumour-cell binding establishes that any event occurring during treatment is caused by the antibody.

Question 3 of 10 A patient develops fever, chills and hypotension during a catumaxomab course. Which interpretation is most appropriate at initial case review?

Consider an inflammatory reaction among the possibilities, but assess the chronology, vital-sign pattern and competing clinical explanations. Classify the event as CRS solely because fever and hypotension occurred after treatment. Exclude an inflammatory reaction because the medicine is administered intraperitoneally. Attribute the event to infection without further assessment because fever is present.

Question 4 of 10 Which patient best fits the current EU use described for Korjuny?

An adult with malignant ascites from an EpCAM-positive carcinoma who is not eligible for further systemic anticancer therapy. An adult with non-malignant ascites and an EpCAM-positive laboratory result. A child with an EpCAM-positive carcinoma who is eligible for systemic anticancer therapy. An adult with any cause of ascites, regardless of tumour type or EpCAM status.

Question 5 of 10 Which case narrative would best support assessment of a suspected infusion-related inflammatory event?

Record the infusion step and dose, start and stop times, symptom sequence, vital signs, investigations, treatment, outcome and any later infusion exposure. Record only the highest temperature and state that the reaction followed treatment. Record the patient's tumour type and the final diagnosis, omitting the infusion chronology. Record the suspected mechanism as CRS and omit the observed symptoms and clinical course.

Question 6 of 10 What is the best practical use of catumaxomab's mechanism when designing case follow-up?

Use it to identify relevant questions about inflammatory features and exposure timing, while basing causality assessment on the full clinical evidence. Use it as proof that any post-dose inflammatory symptom is treatment-related. Use it to exclude non-inflammatory diagnoses such as infection or disease progression. Use it to replace the clinician's diagnosis with a pharmacological explanation.

Question 7 of 10 A report describes fever and tachycardia but does not state that a clinician diagnosed CRS or SIRS. What is the best coding and narrative principle?

Represent the reported symptoms and distinguish them from a suspected CRS/SIRS diagnosis unless the source supports that diagnosis. Always code CRS because fever and tachycardia are compatible with inflammatory activation. Replace the symptoms with SIRS because it is a broader diagnostic label. Omit the symptoms if the mechanism makes an inflammatory event plausible.

Question 8 of 10 Which recordkeeping practice best supports inspection readiness for a serious event?

Maintain traceable records showing the product and dose, evidence reviewed, classification rationale, follow-up and whether new data changed the assessment. Retain only the final coded reaction because the reasoning is not part of the safety record. Keep the original intake but remove later assessments to avoid conflicting interpretations. Record the final benefit–risk conclusion without retaining the evidence used to reach it.

Question 9 of 10 Which statement about Korjuny's current indication avoids unjustified expansion of its scope?

It is for a defined adult population with malignant ascites from EpCAM-positive carcinomas who are not eligible for further systemic anticancer therapy. It is a treatment for any adult with ascites if the tumour expresses EpCAM. It is indicated for all patients with EpCAM-positive cancers, irrespective of ascites or systemic-treatment eligibility. It is a general alternative to systemic anticancer therapy for all adults with carcinoma.

Question 10 of 10 Which allocation of responsibilities is consistent with the article?

The QPPV oversees the marketing authorisation holder's pharmacovigilance system and has access to relevant safety information; the treating clinician remains responsible for patient care. The QPPV makes all treatment decisions for individual patients, while the clinician manages regulatory submissions. The treating clinician is responsible for the marketing authorisation holder's entire pharmacovigilance system. The QPPV's role ends once a case is submitted, and no system oversight is required.

Catumaxomab: Classification, Mechanism, Authorisation History and Pharmacovigilance

Cookie Settings